Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100
Authors
Keywords
-
Journal
Gynecologic Oncology
Volume 178, Issue -, Pages 119-129
Publisher
Elsevier BV
Online
2023-10-19
DOI
10.1016/j.ygyno.2023.09.012
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
- (2022) Razvan Cristescu et al. Journal for ImmunoTherapy of Cancer
- Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
- (2022) Joaquim Bellmunt et al. CLINICAL CANCER RESEARCH
- Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
- (2022) Robert I Haddad et al. Journal for ImmunoTherapy of Cancer
- Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
- (2022) Irene M. Shui et al. Journal for ImmunoTherapy of Cancer
- Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
- (2021) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
- (2021) Razvan Cristescu et al. CLINICAL CANCER RESEARCH
- 338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study
- (2021) Peter Schmid et al. Journal for ImmunoTherapy of Cancer
- ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells
- (2020) Latika Singh et al. MOLECULAR CANCER RESEARCH
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
- (2019) N Colombo et al. ANNALS OF ONCOLOGY
- Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells
- (2019) Lihua Chen et al. CELLULAR ONCOLOGY
- Myeloid-derived suppressor cells coming of age
- (2018) Filippo Veglia et al. NATURE IMMUNOLOGY
- Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
- (2018) Christopher Groth et al. BRITISH JOURNAL OF CANCER
- Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
- (2018) Andrea Varga et al. GYNECOLOGIC ONCOLOGY
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- The Glycolytic Switch in Tumors: How Many Players Are Involved?
- (2017) Li Yu et al. Journal of Cancer
- Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect
- (2016) Xi-sha Chen et al. ACTA PHARMACOLOGICA SINICA
- Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
- (2015) C. Gebhardt et al. CLINICAL CANCER RESEARCH
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor glycolysis as a target for cancer therapy: progress and prospects
- (2013) Shanmugasundaram Ganapathy-Kanniappan et al. Molecular Cancer
- Anticancer Agents That Counteract Tumor Glycolysis
- (2012) Carlotta Granchi et al. ChemMedChem
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More